Giulio Metro (G Metro)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 10

Top Topics

Tyrosine Kinase

Monoclonal Antibody

Brain Metastases

Top Venues

Oncology and therapy

Clinical drug investigation

Lung cancer management

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

This page only lists publications with an associated author ORCID identifier.

Publications

Luca Bertolaccini, Andrea De Giglio, Eleonora Gariazzo, Giulio Metro
A Podcast on Pre- or Perioperative Chemoimmunotherapy for Stage III Non-Small Cell Lung Cancer: Shared Agreement from the Thoracic Surgeon and Oncologist Perspectives. Oncology and therapy (2024)
Luca Bertolaccini, Andrea De Giglio, Eleonora Gariazzo, Giulio Metro
A Podcast on Pre- or Perioperative Chemoimmunotherapy for Stage III Non-Small Cell Lung Cancer: Shared Agreement from the Thoracic Surgeon and Oncologist Perspectives. Oncology and therapy 12 (2) (2024)
Luca Bertolaccini, Andrea De Giglio, Eleonora Gariazzo, Giulio Metro
A Podcast on Pre- or Perioperative Chemoimmunotherapy for Stage III Non-Small Cell Lung Cancer: Shared Agreement from the Thoracic Surgeon and Oncologist Perspectives. Oncology and therapy 12 (2) (2024)
Luca Bertolaccini, Andrea De Giglio, Eleonora Gariazzo, Giulio Metro
A Podcast on Pre- or Perioperative Chemoimmunotherapy for Stage III Non-Small Cell Lung Cancer: Shared Agreement from the Thoracic Surgeon and Oncologist Perspectives. Oncology and therapy 12 (2) (2024)
Sara Baglivo, Martina Mandarano, Guido Bellezza, Vincenzo Minotti, Angelo Bonaiti, Matthias J Fischer, Ilaria Birocchi, Fausto Roila, Niccolò Metelli, Vienna Ludovini, Giulio Metro
Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature. Oncology and therapy 10 (1) (2022)
Giulio Metro, A Gili, D Signorelli, A De Toma, M Garaffa, D Galetta, P Economopoulou, A Friedlaender, B Jimenez, A Collazo-Lorduy, A Addeo, P Chiarini, C Costa, G Mountzios, F Roila
Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 23 (9) (2021)
Giulio Metro, Diego Signorelli, Elio Gregory Pizzutilo, Laura Giannetta, Giulio Cerea, Miriam Garaffa, Alex Friedlaender, Alfredo Addeo, Martina Mandarano, Guido Bellezza, Fausto Roila
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma. Human vaccines & immunotherapeutics 17 (9) (2021)
Giulio Metro, Diego Signorelli
Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions? Lung cancer management 8 (4) (2020)
Giulio Metro, Sara Baglivo, Riccardo Moretti, Guido Bellezza, Angelo Sidoni, Fausto Roila
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review. Oncology and therapy 8 (2) (2020)
Giulio Metro, Sara Baglivo, Annamaria Siggillino, Vienna Ludovini, Rita Chiari, Alberto Rebonato, Guido Bellezza
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. Clinical drug investigation 38 (10) (2018)